What is it about?
Melanoma patients who responded to anti-PD-1 therapy show an increased levels of a protein (bim) in their tumor-reactive immune cells (T lymphocytes).
Featured Image
Why is it important?
Our discovery is important because we are the first to provide a method to predict and monitor how cancer patients may respond to anti-PD-1 immunotherapy.
Perspectives
We are addressing some fundamental questions in cancer immunotherapy: How to identify tumor-reactive T cell responses in cancer patients; Why some cancer patients benefit from anti-PD-1 immunotherapy and some do not. This study basically provided two methods for these questions: 1st, PD-1 and CD11a expression can be used as a marker to identify human tumor-reactive CD8 T cells; 2nd, T cell Bim levels can reflect different responses to anti-PD-1 therapy in cancer patients.
Dr. Haidong Dong
Mayo Clinic College of Medicine
Read the Original
This page is a summary of: T cell Bim levels reflect responses to anti–PD-1 cancer therapy, JCI Insight, May 2016, American Society for Clinical Investigation,
DOI: 10.1172/jci.insight.86014.
You can read the full text:
Contributors
The following have contributed to this page
